TBF Genie Tissulaire

Focus: TBF Genie Tissulaire is a French medical device company specializing in human tissue-derived grafts and regenerative implants, headquartered in Mions with a 30+ year history since 1992. The company operates across ophthalmology, orthopedics, urology, and wound care with a diversified pipeline of allograft and tissue-engineered products.

Ophthalmology

Profile data last refreshed 12h ago · AI intelligence enriched 1w ago

Open Jobs

About TBF Genie Tissulaire

AI assessmentNot Hiring

No open roles listed right now. Follow TBF Genie Tissulaire to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SygeLIX-F + SygeLIX-G

Anal Fistula

Phase 1

Clinical Trials (1)

NCT05638139Treatment of Ano-perineal Fistulas Resistant to Surgical Treatment with a Gel and Plug of Wharton's Jelly

Phase 1

Help build intelligence for TBF Genie Tissulaire

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 20 active programs across multiple therapeutic areas provides exposure to regenerative medicine and tissue engineering across ophthalmology, orthopedics, and urology.
Advanced clinical stage programs including 4 Phase 3 candidates (CARTIPATCH, treated umbilical vein allograft for incontinence, therapeutic lens for keratoconus and myopia) offer visibility into near-term regulatory catalysts.
Established European medical device company with 30+ year operating history provides stability and credibility in the regulated regenerative medicine space.

Watch Out For

No current open job postings (activeJobCount = 0) signals either very limited hiring or organizational challenge in recruitment visibility.
Missing financial data (revenue, funding, cash position, R&D spend) makes it impossible to assess company health, growth trajectory, or job security.
Extremely limited public presence (0 publications, no recent news, no FDA warnings data) suggests either low market profile or lack of transparency—difficult to validate company trajectory independently.

Generated by Claude from TBF Genie Tissulaire's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SygeLIX-Coll-T

Keratitis, Ulcerative

Phase 1

Clinical Trials (1)

NCT05200000Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis

Phase 1

SclerFIX

Enucleated; Eye

Phase 1

Clinical Trials (1)

NCT05236049Use of an Allograft Set-up (SclerFIX) as Replacement of Sclera Graft for Support of Enucleation Implant

Phase 1